Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

Dynamic Biosensors GmbH. (9/1/22). "Press Release: 2bind and Dynamic Biosensors Sign Technology-Service Partnership". Munich & Regensburg.

Products Product heliX® biosensor system
  Product 2 drug discovery services
Index term Index term 2bind–Dynamic Biosensors: switchSENSE technology, 202209– collab technology-service with 2bind using HeliX biosensor system as certified beta customer
Persons Person Schubert, Thomas (2bind GbmH 202209 CEO)
  Person 2 Strasser, Ralf (Dynamic Biosensors 202209 COO + Co-Founder)

Dynamic Biosensors and 2bind, a Contract Research Organization (CRO), today announce that they have signed a technology-service partnership which will enable both companies to further help their customers to accelerate research. The collaboration will enable 2bind to integrate Dynamic Biosensors’ innovative heliX® system into its service portfolio, giving Dynamic Biosensors another highly experienced partner in the areas of certified services and beta-testing of future technologies.

2bind is a highly respected CRO focused on early-stage drug discovery and antibody development, with more than 10 years’ market experience. Its customers will benefit from innovative biophysical binding assays based on Dynamic Biosensor’s proprietary switchSENSE® technology, which leverages DNA nanolevers to determine the size and shape of biomolecules.

Thomas Schubert, CEO of 2bind, commented: “2bind has built up a unique portfolio of biophysical methods and assays to offer customized outsourcing solutions in early drug discovery and antibody development. By integrating Dynamic Biosensors’ cutting-edge heliX® biosensor system, we are gaining another powerful tool to meet our customers’ needs and enhance their research capabilities. The innovative switchSENSE® technology features one of the broadest application ranges of any bioanalytical tool. In addition to direct kinetic binding analysis, it provides detection of avidity / cooperative binding and formation of ternary complexes, which are especially useful for programs involving bi-specific antibodies or PROTAC/molecular glue compounds. The heliX® biosensor also enables the monitoring of conformational changes in proteins, induced for example upon ligand binding. These versatile analysis modes will enrich 2bind’s hit validation capabilities in small molecule and antibody discovery programs. 2bind is proud to become a certified service provider for Dynamic Biosensors’ innovative products and we look forward to driving scientific advances through our expertise in biophysics.”

The partnership positions 2bind as a trusted service partner for the switchSENSE® technology and as a development site for beta-testing novel developments aimed at strengthening Dynamic Biosensors’ product portfolio with cutting-edge tools for biomolecular interaction analysis.

Ralf Strasser, COO of Dynamic Biosensors, said: “2bind and Dynamic Biosensors share a strong commitment to helping our customers achieve scientific breakthroughs. This agreement underlines the importance of early drug discovery for our business. The high-quality information offered by switchSENSE® also helps lower the attrition rate for drug candidates in later, more expensive stages of drug development. Partnering with 2bind supports our mission to bring innovative methodologies to the market and to drive the expansion of the heliX® biosensor system by demonstrating its benefits to researchers around the world.”

Contact Dynamic Biosensors

Dr. Ralf Strasser
+49 89 89 74 544 – 20

Contact 2bind

Dr. Thomas Schubert
+49 941 20000890

About Dynamic Biosensors

Dynamic Biosensors is a provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions. The company commercializes switchSENSE® technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development. The switchSENSE® technology is protected worldwide and only available through Dynamic Biosensors. The company is headquartered in Munich, Germany – a vital center of Europe´s biotechnology industry – and has offices in the United States, the United Kingdom, France, Japan and Singapore.

About 2bind

2bind is a provider of biophysical analytical services with a focus on drug discovery and antibody development, headquartered in Regensburg, Germany. 2bind´s mission is to accelerate customer research by developing and preforming high-end, scalable, and cost-efficient assays based on innovative biophysical technologies. 2bind´s customers benefit from expert knowledge in biophysics and the experience of >1000 projects with >350 customers.

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group World of Partnering Opportunities 650x300px

» top